Article

TNF blockade with certolizumab improves the efficacy of anti-PD-1 and anti-CTLA-4 combination therapy for melanoma

2026-02-14

Abstract excerpt

The phase 1b TICIMEL clinical trial evaluated the safety, tolerability, and anti-tumor activity of combining the immune checkpoint inhibitors (ICI), ipilimumab and nivolumab, with tumor necrosis factor (TNF) blockers, certolizumab or infliximab, to treat advanced melanoma patients. A higher proportion of responses was observed in patients receiving ICI and certolizumab, while patients treated with ICI and inflixim...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 0c88a9e0-38b7-543f-90a1-9baf79a4973d
DOI: 10.64898/2026.02.11.26346073

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

TNF blockade with certolizumab improves the efficacy of anti-PD-1 and anti-CTLA-4 combination therapy for melanomaDOI 10.64898/2026.02.11.26346073Read

Advancements and Challenges in Personalized Therapy for BRAF-Mutant Melanoma: A Comprehensive ReviewSemantic proximity Read

Immune Cell–Cytokine Interplay in NSCLC and Melanoma: A Pilot Longitudinal Study of Dynamic Biomarker InteractionsSemantic proximity Read

Multiomics analysis reveals a Type III driven immune response in immunotherapy-induced toxicity in melanoma and identifies potential new therapeutic targetsSemantic proximity Read

Genome-wide gain-of-function screening characterized lncRNA regulators for tumor immune responseSemantic proximity Read

Checkpoint-blocker induced autoimmunity is associated with pretreatment T cell expression profiles and favourable outcome in melanomaSemantic proximity Read

Identification of CircRNA signature associated with tumor immune infiltration to predict therapeutic efficacy of immunotherapySemantic proximity Read

Predicting response and resistance to immune checkpoint blockade and surgery in melanoma patientsSemantic proximity Read

Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanomaSemantic proximity Read

Thirteen tumor necrosis factor receptor superfamily gene expression in malignancies and their clinical relevance to immunotherapy: a pan-cancer analysisSemantic proximity Read

Combination strategies with PD-1/PD-L1 blockade: current advances and future directionsSemantic proximity Read

Changes in the TCRβ Repertoire and Tumor Immune Signature From a Cutaneous Melanoma Patient Immunized With the CSF-470 Vaccine: A Case Report.Semantic proximity Read

PRMT7 ablation stimulates anti-tumor immunity and sensitizes melanoma to immune checkpoint blockadeSemantic proximity Read